Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer

OBJECTIVE: To evaluate the safety and efficacy of cabozantinib combined with docetaxel. PATIENTS AND METHODS: This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (75 mg/m(2) every 3 weeks with daily prednisone 10 mg) was combined...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BJU Int
Autori principali: Madan, Ravi A., Karzai, Fatima H., Harthy, Munjid Al, Petrylak, Daniel P., Kim, Joseph W., Arlen, Philip M., Rosner, Inger, Theoret, Marc R., Cordes, Lisa, Bilusic, Marijo, Peer, Cody J., Dawson, Nancy A., Couvillon, Anna, Hankin, Amy, Williams, Moniquea, Chun, Guin, Owens, Helen, Marte, Jennifer L., Lee, Min-Jung, Tomita, Yusuke, Yuno, Akira, Trepel, Jane B., Lee, Sunmin, Steinberg, Seth M., Gulley, James L., Figg, William D., Dahut, William L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265825/
https://ncbi.nlm.nih.gov/pubmed/32969563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bju.15227
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi